New hair loss drug enters final testing phase
NCT ID NCT07516561
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new topical drug called APSMNF for male pattern baldness. About 336 men aged 18 to 60 will apply it twice daily for 24 weeks. Researchers will measure changes in hair density using a special camera and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APSMNF (a topical drug applied to the scalp)
- What this could lead to
- If it works, this could offer a new treatment option for male pattern baldness, helping to regrow hair and slow further loss.
- What could go wrong
- This is an early Phase 3 trial, so results are not yet known. The treatment may not work better than existing options, and side effects like skin irritation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA, ANDROGENETIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Geral Investiga Ltda
Campinas, São Paulo, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.